Anavex

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Anavex and other ETFs, options, and stocks.

About AVXL

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome.

CEO

Christopher U. Missling

CEOChristopher U. Missling

Employees

Employees42

Headquarters

New York, New York

HeadquartersNew York, New York

Founded

2004

Founded2004

Employees

Employees42

AVXL Key Statistics

Market cap

854.64M

Market cap854.64M

Price-Earnings ratio

-17.58

Price-Earnings ratio-17.58

Dividend yield

—

Dividend yield—

Average volume

1.17M

Average volume1.17M

High today

$10.04

High today$10.04

Low today

$9.02

Low today$9.02

Open price

$9.13

Open price$9.13

Volume

1.87M

Volume1.87M

52 Week high

$14.44

52 Week high$14.44

52 Week low

$5.03

52 Week low$5.03

AVXL News

TipRanks 3d

Anavex announces development of oral tablet formulation for ANAVEX3-71 program

Anavex (AVXL) Life Sciences announced development of a once-daily oral tablet formulation for the ANAVEX3-71 program. The once-daily modified-release oral table...

TipRanks 5d

Anavex announces publication on oral blarcamesine Phase IIb/III trial

Anavex (AVXL) Life Sciences announced the publication “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Signifi...

People also own

Based on the portfolios of people who own AVXL. This list is generated using Robinhood data, and it’s not a recommendation.